小方制药: 小方制药监事会关于公司2025年限制性股票激励计划相关事项的核查意见内容摘要

к⎧⚗프로그래머스⚗프로그래⚗프로그래머스⚗프로그래⚗프로그래머스⚗프로그래meer.s Berger, the Company’s Supervisory Board has nominated Mr. Jörg Gerber and Mr. Stefan Wolf for re-election as members of the Supervisory Board at the Annual General Meeting.

The Company also announced its financial figures for the first nine months of the fiscal year 2022/23 (ended March 31, 2023). Group sales revenue reached €15.318 billion, up 11% on an exchange rate-adjusted basis. Adjusted EBITDA came in at €2.679 billion, with an adjusted EBITDA margin of 17.5%. Net income amounted to €1.148 billion. The order intake was reported at a record level of €20.048 billion, representing growth of 26% on an exchange rate-adjusted basis. Backlog increased to €31.288 billion.

In terms of divisions, the Semiconductor Manufacturing Technology division saw sales grow 22% to €4.189 billion. The Digital Industries division reported sales of €4.049 billion, an increase of 6%. The Industrial Automation division had sales of €2.989 billion, up 12%. Mobility division sales were €2.028 billion, growing 14%. Smart Infrastructure division sales were €2.063 billion, increasing by 16%.

The Company confirmed its outlook for the fiscal year 2022/23, expecting Group sales revenue to grow by around 10% on an exchange rate-adjusted basis, with an adjusted EBITDA margin between 17% and 18%. The Company plans to propose a dividend of €4.50 per share at the Annual General Meeting.

Note: The provided content appears to be corrupted or encoded incorrectly, making accurate extraction difficult. Please ensure the document is properly formatted for better results.